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Abstract
Background—Clinical guidelines recommend risk stratification of patients with acute
pulmonary embolism (PE). Active cancer increases risk of PE and worsens prognosis, but also
causes incidental PE that may be discovered during cancer staging. No quantitative decision
instrument has been derived specifically for patients with active cancer and PE.
Methods—Classification and regression technique was used to reduce 25 variables prospectively
collected from 408 patients with AC and PE. Selected variables were transformed into a logistic
regression model, termed POMPE-C, and compared with the pulmonary embolism severity index
(PESI) score to predict the outcome variable of death within 30 days. Validation was performed in
an independent sample of 182 patients with active cancer and PE.
Results—POMPE-C included eight predictors: body mass, heart rate >100, respiratory rate,
SaO2%, respiratory distress, altered mental status, do not resuscitate status, and unilateral limb
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swelling. In the derivation set, the area under the ROC curve for POMPE-C was 0.84 (95% CI:
0.82-0.87), significantly greater than PESI (0.68, 0.60-0.76). In the validation sample, POMPE-C
had an AUC of 0.86 (0.78-0.93). No patient with POMPE-C estimate ≤5% died within 30 days
(0/50, 0-7%), whereas 10/13 (77%, 46-95%) with POMPE-C estimate >50% died within 30 days.
Conclusion—In patients with active cancer and PE, POMPE-C demonstrated good prognostic
accuracy for 30 day mortality and better performance than PESI. If validated in a large sample,
POMPE-C may provide a quantitative basis to decide treatment options for PE discovered during
cancer staging and with advanced cancer.
Keywords
Pulmonary embolism; outpatient; risk-stratification; Risk stratification; malignancy; prognosis;
decision rule; treatment
INTRODUCTION
Risk stratification of acute pulmonary embolism (PE) generally refers to the use of objective
criteria to predict the probability of clinical deterioration or death during a short-term
follow-up period after diagnosis. The majority of published literature focuses on
categorizing PE patients as low, moderate, or high risk of death, respiratory failure, or
circulatory failure during the inpatient period or up to 30 days. 1;2 Methods of PE risk
stratification include echocardiography, biomarkers, and scoring systems comprising clinical
variables obtained from history and physical examination. In the emergency department
setting, the category of risk can provide an objective basis to decide how and where to treat
the patient. 1-4 Patients with active malignancy represent a subgroup at particularly high risk
both of developing PE and of having an increased risk of death after diagnosis of PE, when
compared with patients who have no history of cancer or a past medical history of cancer in
remission at the time of PE diagnosis. 5-12 Patients with cancer and their oncologists also
face the conundrum of how and where to treat unsuspected PE that is incidentally
discovered on approximately 2% of computerized tomography pulmonary angiography
scans ordered for the purpose of cancer staging or surveillance.13;14 It can be reasonably
hypothesized that many cancer patients with these incidentally discovered PE desire to be
treated at home, but current literature lacks a decision tool to quantify the short-term
prognosis for patients with active cancer and PE.15 The most widely validated scoring
system for PE is the PESI tool, and a recent randomized trial demonstrated equivalent
outcomes for patients with a low-risk PESI score randomized to have treatment initiated in
the outpatient setting compared with the inpatient setting.16 However, PESI has not been
tested specifically in patients with active cancer or PE. The objective of this study was to
derive a multivariate, quantitative decision tool to assess the probability of death within 30
days among patients with active cancer who present in the outpatient environment with PE,
compare its performance to PESI, and to perform initial validation studies of its prognostic
accuracy using four independent samples of patients with active cancer and PE and to create
a web-based electronic userform of the model for future research use.
METHODS
The prediction instrument was derived as a preplanned secondary analysis of the multicenter
EMPEROR (Emergency Medicine Pulmonary Embolism in the Real World) Registry
dataset, which was collected in 22 community and academic emergency departments in the
United States, from January 1, 2005 until December 29, 2008. The methods of data
collection have been reported elsewhere. 11 Briefly, participating sites in EMPEROR
prospectively collected 264 data elements on 1,880 patients diagnosed with PE in the
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emergency department (ED), including 30 day outcomes. The data collection instrument was
designed to collect detail about risk factors for PE as well as data known to predict adverse
outcomes. The form included demographic data, vital signs, comorbidities, risk factors for
thrombosis, values of biomarkers including troponins and natriuretic peptides,
echocardiographic results, and radiographic results. For many of these elements, additional
detail was collected. Importantly, the malignancy variable was further divided into active
cancer (defined as metastatic disease or cancer under the care of an oncologist), metastatic
malignancy, or inactive cancer (defined as in remission by the patient and no longer under
the active care of an oncologist). That level of detail was collected in response to multiple
studies that found that active cancer, but not cancer in remission, is a risk factor for death
from PE.5-12 We determined which patients with active cancer and PE discovered on
imaging performed for other reasons such as staging or cancer surveillance using a
retrospective chart review for the explicit definition of PE discovered on a CT scan done for
initial staging of newly diagnosed cancer. In this subanalysis, we did not include patients
who had a CT scan done to evaluate for possible worsening of known cancer, or abdominal
CT scans with intravenous contrast that showed a pulmonary vascular filling defects in
slices incidentally found in the lower lung zones. For a separate subanalysis, we also
identified patients who had PE diagnosed in the ED and were discharged from the ED to
home. Patients were followed prospectively for in-hospital adverse outcomes and for
survival until 30 days after the ED visit.
Selection of predictor variables
The selection of variables, their analysis, model construction, goodness of fit, and validation
were performed in accordance with published standards. 17 We first conducted a
comprehensive review of published studies that reported significant predictors of adverse
outcome of PE. 15 This review suggested 24 potential independent variables (appendix). The
dependent variable was mortality at 30 days. The 24 potential predictor variables were
screened for inclusion in the multivariate model using two methods: 1. Data were first
analyzed with classification and regression technique (CART, Salford Systems Inc, San
Diego, CA) 18; 2. Bivariate analysis was then performed to screen for potentially important
differences in means (using unpaired t-test) or frequency (using Chi square) for the 24
variables between survivors and decedents with variables. For a variables to move forward
to the multivariate testing state, the variable had to have both a relative weight >0 from
CART and P<0.1 from bivariate analysis.. Retained continuous predictor variables (e.g.,
heart rate) underwent receiver operating characteristic (ROC) curve analysis to determine
the cutoff corresponding to the lowest likelihood ratio negative for prediction of death at 30
days.
Derivation of the multivariate model
Retained predictors were then entered into a second logistic regression analysis, with the
independent predictor being death at 30 days. Model fit was assessed by P values from the
Pearson's goodness of fit Chi-Square, Hosmer Lemeshow test, the Pseudo (McFadden) R-
square and area under the ROC curve in the derivation dataset (C statistic). 19;20
Preliminary validation of the model
We tested the prognostic accuracy of the derived instrument in six prospectively collected
samples of patients diagnosed with PE in the ED. These studies included one multicenter
sample from the US, 21 three single-center samples from the US, 22;23one single center
registry from New Zealand and one multicenter sample from Europe. 24 The clinical data for
these samples were all collected prospectively by qualified research associates who had
standardized training in data definitions. Data came from the most accurate source or
combination of sources which included the patient in real time, the patient's primary
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physician, the emergency care providers and the medical record. These databases were
reduced to patients with active cancer and PE, and the percentage mortality estimate (i.e.,
the predicted probability of death within 30 days) was then determined by taking the antilog
and solving the logistic regression equation for the P term. Using a criterion standard of 30
day all-cause mortality, prognostic accuracy was assessed from the area under the curve
(AUC) for the ROC curve, with the assumption that lower limit 95% confidence interval for
the AUC greater than 0.5 indicated potential validity. We also calculated the PESI score to
all 1880 patients with PE in the derivation dataset and then for the 408 patients with PE and
active cancer, and compared its prognostic accuracy to POMPE-C based upon AUC under
the ROC and the percentage of the sample with a low risk PESI score (<66 points) and the
30 day rate of death in this low risk group.
Creation of web-based prototype
The validated model was then converted to an electronic form by creating an input form in
Visual Basic designed to explain and capture each variable from the user and output the
numeric probability of death using the derived and validated logit equation. The form was
then uploaded to a server and a universal resource locator address assigned to allow public
access.
RESULTS
Candidate variable selection
To assess the potential significance of all 25 predictor variables, the original EMPEROR
database (N=1,880) was reduced to patients with active cancer and PE, excluding patients
who had comfort care status only. This process excluded 1,346 patients with no history of
cancer, 108 who had a history of cancer thought to be in remission, and 18 patients with
active cancer and comfort care only status, leaving 408 patients with active cancer, of whom
51 (12.5%) died within 30 days of any cause. Table 1 lists the means and frequency data for
the 25 predictor variables for survivors compared with patients who died for the 408 patients
with active cancer and PE. Table 1 also shows the relative weights of each predictor
determined from CART and the bivariate P values. Eight variables had a non-zero weight
from CART and a P<0.1 from either the unpaired t-test or Chi-Square and were thus
retained for the multivariate model.
Derivation of the multivariate model
The retained eight variables were: 1. Body weight, 2. Respiratory rate, 3. SaO2%, 4. Heart
rate over 99 beats/min, 5. Altered mental status, 6. Respiratory distress, 7. Do not resuscitate
status, 8. Unilateral limb swelling. The first three variables are entered as continuous data
and the last five variables are entered as dichotomous values. These variables and their
definitions are presented in Table 2. In logistic regression analysis, all 8 variables were
significant predictors of death, as demonstrated by the lower limit of the 95% confidence
interval for the odds ratios associated with each variable (Table 2). The Pearson Chi-square
goodness of fit P value was 0.94, the Hosmer Lemeshow P value was 0.48, the McFaddens’
R2 was 0.21. When the model was applied to the 408 patients with active cancer and PE in
the derivation dataset, the AUC under the ROC was 0.84 (95% CI: 0.78 to 0.89). When
applied to the entire dataset of 1880 patients with PE, the model had an AUC for the ROC of
0.80 (0.76 to 0.85). When applied to the 108 patients with a history of inactive cancer, the
derived model had an AUC of 0.85 but because only seven of these 108 patients died within
30 days, the confidence intervals were wide (0.66 to 1.0). Taken together, these data indicate
reasonable model fitness and predictive accuracy in the derivation set of patients with cancer
and PE.19;20
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Prognostic accuracy of PESI
When applied to the entire 1880 patients in the derivation sample with PE, the PESI score
demonstrated good overall diagnostic accuracy, with an AUC of 0.79 (0.75 to 0.83), and
610/1880 patients (34%) had PESI<66, and only 5/610 with PESI<66 died within 30 days,
confirming the good overall performance of PESI as tool to identify low-risk patients with
PE in the heterogenous derivation sample. However, when PESI was applied to the 408
patients with active cancer and PE, the AUC was significantly reduced to 0.68 (0.60 to 0.76)
and only 3 patients (0.8%) had PESI<66. None of these three patients died within 30 days.
Examination of higher cutoffs for PESI to allow a larger fraction of the population to be
deemed low risk caused an unfavorable increase of inclusion of patients who died within 30
days. For example, 111/408 patients (27%) with active cancer and PE had a PESI score
<100, and 8/111 (7%) died within 30 days.
Preliminary validation of the model
The six validation samples contained a total of 14,121 patients, of whom 202 had active
cancer and PE+. The database from Europe also did not explicitly record the terms for
altered mental status or do not resuscitate but in accordance with original inclusion and
exclusion requirements for study enrollment, these were assumed to be absent for all
patients. Data were missing [body mass (12), respiratory rate (5) and pulse oximetry (3)] in
20 patients, seven from the European sample and three from the New Zealand sample and
these 20 patients were excluded. Thus, 182 patients had complete data, of whom, 27 died
within 30 days (mortality 15%, 95% CI: 10 to 21%). Table 3 presents the mean percentage
mortality estimate for patients from the individual studies comprising the total validation
sample, stratified by survival status at 30 days. Figure 1 shows the ROC curve derived in the
aggregated sample of all 182 validation patients. The area under the curve was 0.86 (95%
CI: 0.78 to 0.93) indicating good overall discriminatory value in the validation sample.
Figure 2 shows a frequency dot plot of each probability estimate, stratified by survival status
at 30 days.
The percentage estimates of mortality from the logistic equation were examined for cutoffs
that predicted a very low and very high probability of death within 30 days for each patient
in the validation sample. The cutoff of 5% produced a very low probability of death. In the
validation sample, 50 patients (27%) of patients in the validation set with a mortality
estimate of 5% or less died within 30 days. Stated another way, all patients who died had a
mortality estimate >5%, indicating a sensitivity of 27/27 (100%, 95% CI: 88 to 100%) and
106 patients who survived >30 days had a mortality estimate >5% (specificity 50/156 =
32%, 95% CI: 25 to 40%), producing a posterior probability of death equal to 0/50 (95% CI:
0 to 7%). The cutoff of 50% produced a very high probability of death; 13 patients had a
mortality estimate >50%, and 10/13 died (posterior probability 73%, 95% CI: 46 to 95%).
From both the derivation set and the validation set, we identified 16 patients whom we
confirmed to have PE discovered incidentally, of whom none (0%) were discharged from
the emergency department and one died within 30 days, but after hospital discharge. The
mean POMPE-C score for the 15 patients who survived was 5±5%, and 9 of 15 had a score
<5%. The patient who died had a POMPE-C score of 46% and was the only patient with a
do not resuscitate order. We also identified 19 other patients who were discharged from the
ED, none of whom died within 30 days. The mean POMPE-C for these patients was 6±8%
and 14 of 19 had a score ≤5%.
Web-based prototype
The electronic input form was programmed to collect and transform the five dichotomous
and three continuous variables into a numeric probability (P) of death using the formula P =
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100 * (1 - 1 / (1 + Exp(3.718 + DNR*1.551 + RespDist*0.800 + ULS*0.734 + AMS*1.473
+ HR + (RR*0.044) + (Sao2*-0.063) + (bodyweight * -0.012)))). The resultant prototype
device can be tested at http://www.studymaker.com/projects/pompe/index.php
DISCUSSION
We derived POMPE-C to address an unmet need for an accurate prognostic tool in patients
with acute PE and active cancer. The POMPE-C tool demonstrated good overall diagnostic
accuracy in both the derivation dataset (area under the receiver operating characteristic
curve = 0.84, 95% CI: 0.78 to 0.89) and the validation sample (area = 0.86, 0.78 to 0.93) of
patients with PE and active cancer.25 Moreover, in the validation sample, 27% (n=50) of
patients had a POMPE-C estimate ≤5%, and none of these 50 died within 30 days (0/50,
95% CI: 0 to 7%), suggesting clinical utility to the 5% threshold to define low risk in a
future clinical trial designed to increase home treatment of PE for cancer patients. We chose
the 30 day mortality endpoint because this is the primary endpoint for the PESI score, and
Aujesky et al has demonstrated that patients with PESI<66 generally have good outcomes
when treated as outpatients. In patients with active cancer, the prognostic accuracy of the
PESI was significantly degraded when compared with its accuracy in the whole derivation
population, and PESI demonstrated a significantly lower area under the receiver operating
characteristic curve than POMPE-C in the active cancer subgroup. Only 3/408 (0.8%) of
patients with active cancer and PE had a low risk PESI score (<66 points), and raising the
low-risk PESI threshold to 100, such that 27% of the derivation group was considered low
risk, led to an unacceptable 7% death rate at 30 days. Taken together these data indicate that
POMPE-C can accurately prognose PE in patients with active cancer, and indicate that
POMPE-C may be more accurate than PESI for this goal.
A primary motivation of this study stems from the need for a validated clinical pathway in
the management of cancer patients who, in undergoing staging imaging that includes
contrast-enhanced pulmonary vasculature imaging, are incidentally discovered to have PE.
Prior work has suggested that this occurs in approximately 1.5-2.5% of such scans.13;14
Published evidence suggests that not all incidental clots are benign, especially in the case of
larger clots.26;27 Following the work of Aujesky et al, the goal of this effort is to use
POMPE-C in a clinical trial of outpatient management for low risk patients with active
cancer and PE, including those with incidentally discovered PE, and with a POMPE-C
mortality estimate of 5% or less.16 Additionally, for selected patients with advanced cancer
and PE, an accurate quantitative prediction instrument may better align the care patients
want with the care they receive near the end of life.
The scope and selection of prediction variables warrants specific consideration. First, the
data the EMPEROR registry was designed to include including specific variables relevant to
prognosis of cancer patients with PE. We used a rigorous data mining process, including the
combined use of stochastic methods and classification and regression to enhance the
sensitivity and specificity of the final model.28 This process resulted in the selection of eight
predictor variables, five of which we submit are fairly well recognized general predictors of
outcome from PE (heart rate, respiratory rate, SaO2%, respiratory distress, and altered
mental status), as well as three predictors that appear to be more specific to patients with
cancer and PE (body weight, do not resuscitate status, and unilateral limb swelling). Body
mass probably serves as a very crude but reliable surrogate to the stage of cancer, and body
mass was chosen over body mass index (BMI), because it is simpler and BMI did not
improve the model fitness. The “do not resuscitate” (DNR) status can be viewed as both a
predictive and deterministic variable. However, from a probabilistic standpoint, two facts
remain true: 1. When a patient with cancer is diagnosed with PE, the patient's DNR status
can be determined as either positive or negative, and 2. The DNR status strongly influences
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outcome. Thus, we argue that a decision rule that fails to advantage itself of the predictive
power of DNR status will also fail to be as accurate as is reasonably possible. Unilateral
limb swelling probably reflects the worsened prognosis of concomitant DVT either in the
leg or arm, the latter of which is often associated with an indwelling catheter, which may
imply additional vulnerability such as ongoing chemotherapy. Several registries have
demonstrated increased risk of death from PE with concomittant DVT and this factor is
present in the Geneva risk score.29
The selected eight variables were entered into a logistic regression instead of a classification
tree as the final model as the goal was to produce a numeric percentage probability estimate
of death, and because logistic regression often produces better results in validation in studies
of short term prognosis of acute cardiovascular disorders. 30;31 The resulting equation found
all variables significant, and the final model demonstrated good fit in the derivation set, but
most importantly had good accuracy in independent samples that included patients from
multiple countries. Taken together, these methods should confer durable external validity to
the model.
Limitations to this study include the lack of a large prospective validation sample, which
will be the next research step. 32 Neither EMPEROR nor any of the validation studies were
designed to capture patients with incidentally discovered PE on staging CT scans.
Nonetheless, we identified 16 patients with PE discovered in this situation, as well as 19
other patients who were discharged from the ED, and POMPE-C estimated a low risk of
death (i.e., ≤5%) in two-thirds of these patients. The POMPE-C model lacks information
about malignancy type and staging because they were not collected in the derivation sample.
We believe these variables should be collected in a larger validation study and then tested in
simulation analyses to determine if they can improve the already good diagnostic accuracy
of POMPE-C. We defined active cancer using similar language employed by the Well's
score for pretest probability assessment for PE, although we acknowledge that
distinguishing active versus inactive cancer will inherently have some ambiguity especially
in the ED setting. This concern is mitigated somewhat because the area under the ROC for
POMPE-C was 0.85 for patients with inactive cancer, although the confidence intervals
were very wide (0.66 to 1.0). Some users may prefer to use an integer-based scoring system,
derived from the coefficients taken from a logit equation that uses only dichotomized
variables. However, in trial derivation, the process of dichotomizing respiratory rate, pulse
oximetry, and body weight caused a loss of both precision and accuracy. The creation of a
web-based userform fits into the larger initiative of many health care systems to convert
medical records into an electronic format. Moreover, our prior published experience has
suggested that emergency medicine clinicians frequently commit errors in their recall and
use of decision rules for pulmonary embolism. 33;34
Conclusion
This study reports the derivation and initial validation of an eight variable quantitative
decision rule that demonstrated good overall accuracy in predicting all-cause, near-term
mortality for patients with active cancer and acute pulmonary embolism. Further validation
in a larger sample of patients with active cancer and PE will be necessary.
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Figure 1.
Receiver operating characteristic curve using the percentage probability estimate of
mortality from the logistic regression equation as the diagnostic test, and the outcome was
30 day mortality in the validation sample.
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Figure 2.
Dot plot of the estimated probability of death from the logistic regression equation (Y axis),
stratified according to survival status at 30 days (X axis).
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Table 2
Odds ratios for the eight predictor variables from logistic regression
Variable Coefficient
Odds Ratio Bias corrected 95% CI
Intercept 3.718
Patient weight (lb)1 1.551 0.99 0.98 to 1
Highest respiratory rate (breaths/min)2 0.7996 1.05 1.01 to 1.09
SaO2 (%)3 0.734 0.94 0.89 to 0.99
Heart rate >99 beats/min4 1.473 2.8 1.38 to 5.64
Altered mental status5 1.027 4.36 1.47 to 13
Respiratory distress6 0.044 2.22 1.12 to 4.43
Do not resuscitate status7 -0.063 4.72 1.75 to 12.76
Unilateral limb swelling8 -0.0116 2.08 1 to 4.36
Variable definitions:
1
Body weight measured or by patient's estimate
2
Highest documented respiratory rate within previous six hours
3
Most recent pulse oximetry measured with patient breathing room air.
4
Positive if heart rate documented over 99 beats/min in previous six hours.
5
Positive if patient has acute impairment in consciousness, new disorientation, delirium, or confusion
6
Positive if the patient shows obvious anxiety from dyspnea or evidence of increased work of breathing
7
Positive for new or existing verbal or written desire of patient to not be resuscitated from death
8
Positive for either a leg or arm has new, presentlly noticeable swelling causing it to be asymmetrical compared with the contralateral limb.
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